| Course | NUR-7600 Psychopharmacology and Neuroscience Foundations Across the Lifespan |
|---|---|
| Module | Module 2 |
| Paper type | Prescribing case: pharmacogenetics and pharmacokinetics |
| Length | About 1,044 words, 6 pages |
| Format | APA 7 student paper |
| School | Thomas Edison State University |
| Program | M.S. in Nursing, Psychiatric Mental Health Nurse Practitioner |
| Updated | October 2026 |
Free sample paper for NUR 7600 Module 2
Twenty Milligrams That Never Reached Her Brain: CYP2C19 Ultrarapid Metabolism, a Failed Escitalopram Trial and a Guideline-Based Switch
Student Name
M.S. in Nursing, Psychiatric Mental Health Nurse Practitioner, Thomas Edison State University
NUR-7600: Psychopharmacology and Neuroscience Foundations Across the Lifespan
Mentor Name
Month Day, Year
Twenty Milligrams That Never Reached Her Brain: CYP2C19 Ultrarapid Metabolism, a Failed Escitalopram Trial and a Guideline-Based Switch
Introduction
Ms. P. is invented for teaching: 27, a paralegal in a Jersey City firm, worrying her way through generalized anxiety disorder. For two years she has worried most days about work, her parents' health and money, with muscle tension, poor sleep and trouble concentrating. Her Generalized Anxiety Disorder 7 score was 16. Her previous provider started escitalopram 10 milligrams and increased it to 20 milligrams after four weeks. After ten weeks, her score is 15, essentially unchanged. Unusually, she reports almost no side effects, not even the nausea or sexual effects many patients notice. Before choosing a new drug, her new psychiatric nurse practitioner reviewed adherence and ordered a pharmacogenetic panel. This paper explains the result and the plan.
First, Rule Out the Common Causes
Most antidepressant failures are not genetic. Before attributing Ms. P.'s lack of response to her genes, the nurse practitioner checked the common causes: adherence, which she confirmed with pharmacy fill records showing monthly refills on time; the adequacy of the trial, which at 20 milligrams for ten weeks met usual standards; interacting drugs and substances, of which there were none; and the diagnosis, which remained generalized anxiety without bipolar features, substance use or a medical cause such as hyperthyroidism. Only after these were excluded did the genotype become the most likely explanation. Checking the pharmacy record, rather than only asking, matters because many patients overstate adherence out of embarrassment.
How CYP2C19 Handles Escitalopram
Escitalopram is cleared mainly by the liver enzyme CYP2C19, with contributions from CYP3A4 and CYP2D6. The CYP2C19 gene varies between people. Some alleles produce no working enzyme, some reduced function and one, the *17 allele, increased function because of a change in the gene's promoter that raises enzyme production. A person with two increased-function alleles is classified as an ultrarapid metabolizer. In such a patient, escitalopram is metabolized faster than usual, so the same dose produces lower blood levels and may not reach a therapeutic concentration in the brain.
The pattern fits Ms. P. exactly: no benefit and almost no side effects, as if she had been taking a much lower dose. Side effects of SSRIs, like their benefits, depend on concentration, so their absence is a clinical clue that levels may be low.
A blood level of escitalopram could confirm the suspicion, and some laboratories offer it. It was not ordered here because the genotype already explained the likely cause and would guide the next choice, while a single level, drawn at an unknown time after the dose, would have added cost without changing the plan. In a patient without a genotype result, or with an unexpected one, therapeutic drug monitoring can be a useful step.
What the Guidelines Recommend
CPIC, the pharmacogenetics consortium, writes guidance for acting on genotypes a patient already has, not for deciding who should be tested. Hicks et al. (2015) first addressed CYP2D6 and CYP2C19 for SSRIs, and Bousman et al. (2023) updated and expanded the guidance to more antidepressants. For someone whose CYP2C19 runs ultrarapid, the 2023 update advises choosing a different suitable antidepressant, one that leans less on that enzyme, rather than citalopram or escitalopram. Raising the escitalopram dose above the labeled maximum is not recommended, because the dose-response relationship and the safety of such doses, including effects on the QT interval, are not established.
| CYP2C19 phenotype | Escitalopram recommendation |
|---|---|
| Ultrarapid metabolizer | Consider an alternative not mainly cleared by CYP2C19 |
| Normal metabolizer | Standard dosing |
| Poor metabolizer | Consider a lower dose or an alternative |
Choosing the Alternative
Several options fit the guideline. Sertraline is partly metabolized by CYP2C19 but has several other pathways, and the 2023 guideline supports standard starting doses in ultrarapid metabolizers, with titration based on response. Venlafaxine, a serotonin-norepinephrine reuptake inhibitor, is metabolized mainly by CYP2D6, and her panel showed normal CYP2D6 function. Both are approved or widely used for generalized anxiety. Sertraline is chosen because of its tolerability, its low cost and because Ms. P. is considering pregnancy in the next few years. In a network meta-analysis of 522 trials, sertraline was among the antidepressants that patients were most likely to keep taking (Cipriani et al., 2018), which matters for a patient whose first trial left her discouraged. Venlafaxine remains the next option if sertraline fails, and its dependence on CYP2D6, which is normal in her, means her genotype would not stand in the way.
The Cross-Taper and Order
Escitalopram is reduced to 10 milligrams for one week while sertraline is started at 25 milligrams daily, then escitalopram is stopped and sertraline increased to 50 milligrams. Because her escitalopram levels were probably low, discontinuation symptoms are unlikely, but she is warned of dizziness or irritability. Sertraline will be titrated by 50 milligrams every two to four weeks according to response and tolerance, up to 200 milligrams. She repeats the GAD-7 at weeks four and eight, and halving her score of 15 will count as a response.
Recording and Sharing the Result
Her genotype result is entered into the electronic record as a permanent finding with clinical decision support, because it affects other medicines, including proton pump inhibitors such as omeprazole, the antiplatelet clopidogrel, voriconazole and some other antidepressants. She is given a copy of the report and taught that the result does not change over her lifetime. She is also told what the test cannot do: it does not predict whether any drug will work, only how her body will handle drugs that use this enzyme.
Ethical Considerations
Pharmacogenetic results reveal inherited information about relatives as well as the patient. Her parents and siblings may share the variant. Ms. P. can decide whether to tell them. The result is kept within her medical record under the same protections as other health information.
Her brother, for one, takes omeprazole for heartburn, a drug that also runs through CYP2C19.
Conclusion
Ms. P.'s escitalopram failed because her CYP2C19 enzyme cleared it too quickly, a conclusion reached only after adherence, dose, duration and diagnosis were checked. Following the 2023 CPIC guideline, she is switched to sertraline at standard doses with titration. Her result now lives in her chart for every future prescriber, and she knows both its uses and its limits.
References
Bousman, C. A., Stevenson, J. M., Ramsey, L. B., Sangkuhl, K., Hicks, J. K., Strawn, J. R., Singh, A. B., Ruaño, G., Mueller, D. J., Tsermpini, E. E., Brown, J. T., Bell, G. C., Leeder, J. S., Gaedigk, A., Scott, S. A., Klein, T. E., Caudle, K. E., & Bishop, J. R. (2023). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clinical Pharmacology and Therapeutics, 114(1), 51-68. https://doi.org/10.1002/cpt.2903
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., Egger, M., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Tajika, A., Ioannidis, J. P. A., & Geddes, J. R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. The Lancet, 391(10128), 1357-1366. https://doi.org/10.1016/S0140-6736(17)32802-7
Hicks, J. K., Bishop, J. R., Sangkuhl, K., Müller, D. J., Ji, Y., Leckband, S. G., Leeder, J. S., Graham, R. L., Chiulli, D. L., LLerena, A., Skaar, T. C., Scott, S. A., Stingl, J. C., Klein, T. E., Caudle, K. E., & Gaedigk, A. (2015). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clinical Pharmacology and Therapeutics, 98(2), 127-134. https://doi.org/10.1002/cpt.147
NUR 7600 Module 2 instructions, in plain terms
Genes and drug handling appear together in the NUR-7600 catalog wording, so this second module, built without access to a public syllabus, puts both to work on one failed antidepressant trial. Expect a paper in which a genotype or a kinetic factor, such as an interaction or organ impairment, explains a treatment failure or adverse effect, and in which you apply a pharmacogenetic guideline to choose and dose a new drug. Some classrooms supply a genotype report to interpret. Check the directions. Rule out common causes of nonresponse first, use the current guideline and explain what the test can and cannot tell the patient. Say why you did or did not order a drug level.
How the NUR 7600 Module 2 example is put together
The case opens with a paralegal whose escitalopram failed after ten weeks with almost no side effects. A section checks adherence, trial adequacy, interactions and diagnosis before turning to genetics. CYP2C19 metabolism and the increased-function allele are explained, and the lack of side effects is read as a clue. The CPIC guidelines are summarized with a phenotype table. Sertraline and venlafaxine are compared, and sertraline is chosen with reasons. The cross-taper and titration plan follows. Recording the result, other affected drugs, what the test cannot predict and the ethics of shared genetic information complete the paper before the conclusion. A paragraph explains why a blood level was not needed once the genotype was known.
Where the marks sit in the NUR 7600 Module 2 rubric
Pharmacogenetic cases are graded on correct interpretation of the genotype and phenotype, accurate explanation of the kinetic consequence, correct application of the current guideline and a safe, complete plan for switching drugs. Mentors look for common causes of nonresponse to be excluded first and for the limits of testing to be explained. Recording the result and identifying other affected drugs shows systems thinking. Ethical attention to relatives is often credited. Cite the 2023 CPIC update by year, use allele and phenotype terms exactly and keep the APA tidy. A table of phenotype recommendations helps when it is accurate, and a note on when therapeutic drug monitoring would add value shows a complete grasp of the kinetic tools available.
NUR 7600 Module 2 help: mistakes that cost marks
The most common error is misreading phenotypes, for example treating an ultrarapid metabolizer as needing a lower dose. Higher enzyme activity means lower drug levels. Students also jump to genetics without checking adherence or the adequacy of the trial. Cite the current guideline, since recommendations were updated in 2023. Do not raise doses above labeled maximums to compensate. Explain the cross-taper. Note other drugs affected by the same enzyme. Tell the patient what the test cannot predict, and say when a drug level would help. Name the next option if the switch fails. Attach the genotype report from your NUR-7600 case and the desk will interpret it and write the plan; your first request costs nothing.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official Thomas Edison State University document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.
More NUR 7600 and M.S. in Nursing, Psychiatric Mental Health Nurse Practitioner sample papers
- NUR 7600 Module 1: Neurotransmission Case: Why a First SSRI Takes Weeks to Help
- NUR 7600 Module 3: Antipsychotic Case: First-Episode Psychosis and Metabolic Risk
- NUR 7600 Module 4: Lifespan and Controlled Substances Case: Methylphenidate for a 9-Year-Old
- NUR 7600 Module 5: Adverse Events Case: Risperidone, the Boxed Warning and a Taper in Dementia
- NUR 7600 Module 6: Toxicity Case: Lithium Maintenance, Levels and Interactions
- NUR 7631 Module 6: Early-Onset Psychosis Case: Antipsychotic Choice and Metabolic Monitoring
- NUR 7620 Module 5: Later-Life Therapy Case: Problem-Solving Therapy and Caregiver Support
- NUR 7641 Module 5: Adolescent Suicide Risk Case: ASQ Screening, Safety Planning and DBT
- NUR 7642 Module 3: Opioid Use Disorder Case: Buprenorphine Start, Overdose Risk and Retention in Treatment
NUR 7600 Module 2 questions, answered
Where can I find a free NUR 7600 Module 2 sample paper?
This page holds it from title page to references. It explains why escitalopram failed in a CYP2C19 ultrarapid metabolizer and switches her to sertraline under the 2023 CPIC guideline.
What is a CYP2C19 ultrarapid metabolizer?
A person with two increased-function CYP2C19 alleles, such as two copies of the *17 allele, whose enzyme clears drugs like escitalopram faster, lowering blood levels.
What does CPIC recommend for escitalopram in ultrarapid metabolizers?
Move to a suitable antidepressant that depends less on CYP2C19, and do not push escitalopram past its labeled maximum.
Should I order pharmacogenetic testing for every antidepressant failure?
Check adherence, dose, duration, interactions and diagnosis first. Testing helps when these are adequate and the pattern, such as no side effects, suggests a kinetic cause.
Which other drugs does CYP2C19 affect?
Citalopram and escitalopram, several proton pump inhibitors, clopidogrel, voriconazole and some tricyclic antidepressants, among others.